comparemela.com

Latest Breaking News On - Iaso biotherapeutics - Page 1 : comparemela.com

IASO Bio Announces CT103A Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track (FT) Designations by the FDA

/PRNewswire/ IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative.

Equecabtagene autoleucelA equecabtagene autoleucelChina national medical products administrationDrug administrationInnovent biologics incRegenerative medicine advanced therapyFast trackNew drug applicationBreakthrough therapy designationOrphan drug designationNeuromyelitis optica spectrum disorderInnovent biologicsCentury cures actAccelerated approvalPriority reviewNational medical products administration

IASO Bio Raises Nearly $75 Million in Series C1 Funding

/PRNewswire/ IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative.

Equecabtagene autoleucelAlan fuUmoja biopharmaJianhua zhaoChina national medical products administrationShanghai guoxin investment developmentShanghai waigaoqiao free trade zone groupDrug administrationApproaches commercializationShanghai guoxin investmentEfung capitalNew drug applicationNational medical products administrationInvestigational new drugBreakthrough therapy designationOrphan drug designation

Iaso Bio Raises Nearly $75M in Series C1 Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Equecabtagene autoleucelIaso biotherapeuticsIaso bioShanghai guoxin investment developmentShanghai waigaoqiao free trade zone groupNational medical products administrationDrug administrationShanghai guoxin investmentEfung capitalNew drug applicationInvestigational new drugBreakthrough therapy designationOrphan drug designationNeuromyelitis optica spectrum disorder

U S FDA Approves Clinical Trial Application for IASO Bio s BCMA CAR-T CT103A for Relapsed/Refractory Multiple Myeloma

/PRNewswire/ IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative.

United statesWen maxwell wangResearch conferenceChina national medical products administrationEuropean hematology associationDrug administrationInvestigational new drugNational medical products administrationChief executive officerNew drug applicationBreakthrough therapy designationOrphan drug designationNeuromyelitis optica spectrum disorderIaso biotherapeutics

World s First CAR-T for NMOSD Treatment, IASO Biotherapeutics Equecabtagene Autoleucel, Receives IND Approval by NMPA

/PRNewswire/ IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative.

Neuromyelitis opticaEquecabtagene autoleucelWen maxwell wangChina national medical products administrationDrug evaluationNational medical products administrationNeuromyelitis optica spectrum disorderCytokine release syndromeExpanded disability status scaleChief executive officerChief medical officerInvestigator initiated trialNew drug applicationBreakthrough therapy designationOrphan drug designationDrug designation

vimarsana © 2020. All Rights Reserved.